A distinct biological fingerprint distinguishes diseased from healthy tissue
For generations, adenomyosis has quietly diminished the lives of roughly one in five women of reproductive age, yet medicine has offered little beyond hormonal suppression or the removal of the uterus itself. Researchers at the University of Liverpool have now mapped the molecular terrain of adenomyosis lesions with unprecedented precision, revealing a distinct biological signature that explains why the disease persists and, crucially, suggesting that it may be reversible. The work marks a turning point in a long silence — the beginning of a path toward treatments that could spare both the uterus and the possibility of new life.
- A condition affecting 20% of women of reproductive age has for decades been met with only two blunt instruments: hormones that suppress fertility or surgery that ends it permanently.
- Using spatial transcriptomics — applied to human uterine tissue for the first time — researchers discovered that adenomyosis lesions carry a molecular fingerprint distinct from surrounding healthy tissue, behaving like the womb's deepest, most durable layer.
- Ongoing inflammation and disrupted cellular energy production within the lesions help explain the severe pain and heavy bleeding women endure, giving scientists concrete biological targets to pursue.
- Existing and experimental drugs have already been identified that could potentially reverse the lesions' biological changes, opening the door to clinical trials without surgery or fertility-suppressing hormones.
- The research is foundational rather than finished — but for the first time, clinicians and scientists share a detailed map of what they are trying to treat.
A research team at the University of Liverpool has produced the most precise molecular map yet of adenomyosis lesions, raising the prospect of treatments that neither remove the uterus nor suppress a woman's ability to conceive. The work, led by Professor Dharani Hapangama's gynecology group, addresses a disease that affects roughly one in five women of reproductive age — a prevalence that has long outpaced the medical attention devoted to it.
Adenomyosis occurs when tissue resembling the womb's inner lining invades the muscular wall beneath it, causing heavy bleeding, severe pain, and in some cases fertility complications. Despite its reach, the condition has been poorly understood at the molecular level, leaving doctors with a narrow toolkit: hormone therapies that halt menstruation and fertility, or hysterectomy. The assumption that it primarily affected older women approaching menopause has since collapsed, as younger women trying to conceive increasingly recognize themselves in the diagnosis.
Dr. Alison Maclean and her colleagues applied spatial transcriptomics to human uterine samples — a first for the field — allowing them to map gene activity across different cell types while preserving the tissue's spatial architecture. Comparing diseased and healthy tissue from the same uterus, they identified a distinct biological signature within the lesions. The invading tissue, they found, shares characteristics with the womb's deepest, most self-renewing layer, helping explain why adenomyosis is so persistent. They also documented inflammation and disrupted energy production within the diseased tissue — processes that likely drive the symptoms women experience.
Most significantly, the molecular data pointed toward existing and experimental drugs capable of reversing some of these biological changes. These are not distant hypotheticals but compounds already in use or development, now candidates for clinical trials. Maclean described the goal plainly: therapies that target adenomyosis directly, leave healthy tissue intact, and preserve fertility. The map now exists. The work of following it to effective treatment has begun.
A team of researchers at the University of Liverpool has mapped the molecular landscape of adenomyosis lesions with enough precision to imagine a future where doctors could treat the condition without removing the uterus or flooding the body with hormones that prevent pregnancy. The work, led by Professor Dharani Hapangama's gynecology research group, represents a shift in how scientists understand a disease that affects roughly one in five women of reproductive age—a staggering prevalence that has nonetheless remained understudied and underappreciated in medical research for decades.
Adenomyosis occurs when tissue resembling the womb's inner lining invades the muscular wall beneath it. The result is often severe: heavy menstrual bleeding, debilitating pain, and in some cases, difficulty conceiving or carrying a pregnancy to term. For years, the condition was assumed to be primarily a problem of older women approaching menopause. That assumption has crumbled. Younger women, including those actively trying to have children, now recognize themselves in descriptions of the disease. Yet the medical toolkit for treating it has barely evolved. Doctors typically offer hormone-based therapies—which work by suppressing menstruation and fertility—or hysterectomy, the surgical removal of the uterus itself. The narrowness of these options reflects a deeper gap: scientists have not fully understood what makes adenomyosis tissue different from healthy tissue at the molecular level.
Dr. Alison Maclean and her colleagues set out to close that gap using spatial transcriptomics, a technique that maps which genes are active in different cell types while keeping the tissue's architecture intact. This was the first time the method had been applied to human uterine samples. The advantage was immediate: researchers could compare diseased and healthy tissue from the same uterus side by side, preserving the spatial relationships that other methods destroy. What they found, published in Science Advances, was a distinct biological signature within the adenomyosis lesions—a molecular fingerprint that distinguishes them from surrounding normal tissue.
The lesions, the team discovered, share characteristics with the deeper, more stable layer of the womb lining. This finding offers a clue to how adenomyosis takes hold and persists: the invading tissue behaves like the womb's basal layer, which is designed to be durable and self-renewing. The researchers also documented ongoing inflammation and disrupted energy production within the diseased tissue, processes that likely drive the pain and bleeding women experience.
Perhaps most promising, the molecular data revealed existing drugs and experimental medicines that could potentially reverse some of the biological changes observed in the lesions. These are not theoretical possibilities. They are compounds already in use or in development that could be tested in clinical trials. The implication is clear: a treatment path exists that does not require surgery, that does not necessarily demand hormonal suppression, and that could preserve both the uterus and a woman's ability to conceive.
Maclean emphasized the stakes. The goal is to develop therapies that directly target adenomyosis while leaving healthy tissue untouched, allowing women to avoid major surgery and protect their fertility. The work is foundational—further investigation is needed before any new drug reaches patients. But for the first time, researchers have a detailed map of what they are trying to treat. The next phase is to follow that map to treatments that work.
Notable Quotes
By identifying the features that distinguish diseased tissue from healthy tissue, we are laying the groundwork for treatments that could directly target the condition while preserving the uterus and normal womb lining.— Dr. Alison Maclean, NIHR clinical lecturer
The Hearth Conversation Another angle on the story
Why has adenomyosis been so neglected in research if it affects one in five women?
Part of it is historical. The condition was thought to be rare and confined to older women, so it didn't attract funding or attention. Even now, diagnosis is difficult—you often need an MRI or surgery to confirm it. That invisibility compounds itself. If doctors can't easily diagnose it, they don't study it. If they don't study it, they don't develop treatments. Women suffer in silence.
What makes spatial transcriptomics different from previous methods?
Earlier techniques required grinding up tissue, which destroys the spatial relationships between cells. You lose the architecture. Spatial transcriptomics lets you see which genes are active in which cells while keeping everything in place. For adenomyosis, that matters enormously because the disease is fundamentally about tissue invading where it shouldn't be. You need to understand the geography.
The finding that adenomyosis lesions resemble the deeper womb lining—what does that tell us?
It suggests the disease isn't random. The invading tissue isn't just misplaced; it's adopting the characteristics of a layer designed to be stable and self-renewing. That's why adenomyosis persists and worsens over time. It's not just inflammation. It's tissue behaving like it belongs there.
If existing drugs could reverse these changes, why haven't they been used before?
Because nobody knew which drugs to test. You can't target a disease you don't understand at the molecular level. Now that researchers have identified the specific biological changes, they have a rational basis for selecting candidates. It's the difference between throwing darts blindfolded and aiming at a visible target.
What happens next?
Clinical trials. The researchers need to test whether these drugs actually work in women with adenomyosis, whether they're safe, and whether they preserve fertility. That takes years. But for the first time, there's a plausible path forward that doesn't end in surgery.